Ceza Formulations Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 17-07-2024
- Paid Up Capital ₹ 1.50 M
as on 17-07-2024
- Company Age 25 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 7.80 M
as on 17-07-2024
- Satisfied Charges ₹ 1.03 Cr
as on 17-07-2024
- Revenue 58.59%
(FY 2023)
- Profit 14.48%
(FY 2023)
- Ebitda -1.82%
(FY 2023)
- Net Worth -38.90%
(FY 2023)
- Total Assets -4.27%
(FY 2023)
About Ceza Formulations
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.50 M.
The company currently has active open charges totaling ₹7.80 M. The company has closed loans amounting to ₹1.03 Cr, as per Ministry of Corporate Affairs (MCA) records.
Anil Vyas, Krishnakant Mundra, Mimoh Paliwal, and One other member serve as directors at the Company.
- CIN/LLPIN
U24232MP1999PTC013421
- Company No.
013421
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Mar 1999
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Indore, Madhya Pradesh, India
- Telephone
- Email Address
- Social Media-
What products or services does Ceza Formulations Private Limited offer?
Ceza Formulations Private Limited offers a wide range of products and services, including Digestive System Drugs & Medicines, Digestive Drugs, Common Disease Medicines, Pharmaceutical Tablets, Nutraceuticals & Dietary Supplements, Multivitamin Syrup & Drops.
Who are the key members and board of directors at Ceza Formulations?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anil Vyas  | Director | 13-Dec-2014 | Current |
| Krishnakant Mundra | Director | 10-Nov-2014 | Current |
| Mimoh Paliwal | Director | 10-Nov-2014 | Current |
| Narendra Dalawat | Director | 11-Jul-2016 | Current |
Financial Performance of Ceza Formulations.
Ceza Formulations Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 58.59% increase. The company also saw a substantial improvement in profitability, with a 14.48% increase in profit. The company's net worth observed a substantial decline by a decrease of 38.9%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ceza Formulations?
In 2023, Ceza Formulations had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Exponential Export Solutions Private LimitedActive 4 years 1 month
Krishnakant Mundra is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 17 Dec 2018 | ₹7.80 M | Open |
Others Creation Date: 24 Oct 2016 | ₹9.25 M | Satisfied |
State Bank Of India Creation Date: 25 Apr 2001 | ₹0.50 M | Satisfied |
How Many Employees Work at Ceza Formulations?
Ceza Formulations has a workforce of 8 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ceza Formulations, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ceza Formulations's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
